Skip to main content
Premium Trial:

Request an Annual Quote

Unigene Laboratories, Queen Mary U of London, InnovaSafe, Competitive Tech, Santarus, Georgia Biomedical Partnership, Eden Biosciences, U of Manchester

Unigene Licenses Inflammatory, Cardiovascular Drug Candidates From Queen Mary, U of London
Unigene Laboratories said last week that it has acquired from Queen Mary, University of London, exclusive commercial rights to a combination therapy with potential application in treating inflammatory diseases, and a peptide that could be used to treat certain cardiovascular conditions.
Both technologies are being developed in the laboratory of Mauro Perretti, professor of immunopharmacology at the William Harvey Research Institute, part of Queen Mary’s School of Medicine and Dentistry, Unigene said.
Terms of the deal call for Unigene, based in Fairfield, NJ, to gain rights to inventions already identified and to future developments in exchange for research funding of approximately $400,000 per year over the next three years, milestones based on clinical and commercial progress, and royalty payments representing an undisclosed percentage of Unigene’s revenues.
The specific technologies licensed by Unigene and developed in the Perretti lab include methods of combining calcitonin and various glucocorticoids to treat various inflammatory conditions; and methods related to the development of the natural protein annexin and its smaller peptide fragments to treat strokes and heart attacks, Unigene said.

InnovaSafe Licenses Competitive Tech’s BioEscrow Product; Will Exclusively Market to Non-Academics Worldwide
Competitive Technologies said last week that it has sublicensed to InnovaSafe exclusive worldwide rights to market its BioEscrow service to law firms and life science, biotechnology, and pharmaceutical companies.
Competitive Technologies, or CTT, based in Fairfield, Conn., said it will retain the rights to market BioEscrow directly to academic research institutions.
BioEscrow, a biological material deposit service, is the product of an alliance between CTT and American Type Culture Collection. ATCC will continue to act as the escrow agent for BioEscrow.
Formed in 2005, BioEscrow provides neutral, third-party assistance to academic research institutions and companies that are exchanging proprietary biological materials, information, or technology as part of a license agreement or other arrangement.

Santarus’s License of Missouri IP Faced No Third-Party Opposition in EU as Deadline Ends
Santarus said last week that it has received a notice from the European Patent Office that no third party oppositions were filed against a patent it has licensed from the University of Missouri related to treating gastrointestinal disorders.
Specifically, Santarus said that no opposition was filed against EPO Patent Grant No. 1246622, which relates to pharmaceutical compositions in the form of a non-enteric coated tablet and comprising proton pump inhibitors and one or more buffers.
The EPO issued a notice of the publication of the grant on Sept. 27, 2006, and the period of opposition required under European patent law expired on June 27, 2007.
The European patent expires in January 2021, Santarus said.
Santarus has an exclusive, worldwide license agreement with the University of Missouri for patents and pending patent applications relating to specific formulations of PPIs with antacids and other buffering agents. Currently, five US patents have been issued and several US patent applications are pending, Santarus said.

Georgia Biomedical Partnership is Now GaBio
The Georgia Biomedical Partnership last week said that it has changed its name to Georgia Bio, or GaBio for short.
The new GaBio represents more than 290 companies, universities, research institutes, government groups, and other business organizations dedicated to promoting the state’s life sciences industry.
GaBio said in a statement that the new name reflects a strategy to reinvent the association into “a more aggressive champion of life sciences innovation across all of Georgia’s major industry sectors.”

Eden Biosciences, U of Manchester to Co-Develop Macular Degeneration, Cancer Therapies
Eden Biodesign said last week that it has been selected by the University of Manchester Intellectual Property Limited to provide a range of services for developing a novel therapeutic for treating macular degeneration and cancer.
Paul Bishop, a professor in the University of Manchester School of Medicine who led the team that discovered the new therapeutic, has been awarded a grant from the National Biomanufacturing Center Access Fund towards the cost of the project.
The project will take place at the NBC, operated by Eden Biodesign and funded by Northwest Regional Development Agency, the European Regional Development Fund, and the Department of Trade and Industry.
Eden Biodesign is an international biopharmaceutical development and manufacturing service business that provides consultancy, development, and manufacturing services to large pharmaceutical companies, biotech companies, charities, and academic groups across Europe, the US, and Asia.
The University of Manchester Intellectual Property Limited is the managing agent of intellectual property commercialization for the university.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.